Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 9/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15851029 | 0.93 | GPR35 (0.68) | GPR35MEN1KMT2AHTTGALR3 | |
| SCHEMBL1600086 | 0.90 | GPR35 (0.65) | GPR35MEN1KMT2AHTTGALR3 | |
| SCHEMBL397532 | 0.89 | GPR35 (0.62) | GPR35MEN1KMT2AHTTGALR3 | |
| SCHEMBL19497421 | 0.88 | GPR35 (0.78) | GPR35MEN1KMT2AHTTGALR3 | |
| SCHEMBL69563 | 0.88 | GPR35 (1.00) | GPR35MEN1KMT2AHTTGALR3 | |
| SCHEMBL1600191 | 0.87 | GPR35 (0.61) | GPR35MEN1KMT2AHTTGALR3 | |
| SCHEMBL5732555 | 0.87 | GPR35 (0.61) | GPR35MEN1KMT2AHTTGALR3 | |
| SCHEMBL70416 | 0.86 | GPR35 (0.59) | GPR35MEN1KMT2AHTTGALR3 | |
| SCHEMBL690372 | 0.84 | ERN1 (0.59) | GPR35XDH | |
| SCHEMBL1600577 | 0.84 | GPR35 (0.57) | GPR35MEN1KMT2AHTTGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114480295-A | Hybridoma cell strain capable of secreting butralin-resistant monoclonal antibody and application thereof | 江南大学 | 2022-05-13 | — | — | CN | claimed |
| EP-3053992-A1 | Biodiesel | LANXESS Deutschland GmbH (DE) | 2016-08-10 | — | — | EP | claimed |
| US-4395572-A | Process for preparing N-alkyl-nitroanilines | UNION CARBIDE CORPORATION (US) | 1983-07-26 | — | — | US | claimed |
| US-4289907-A | Process for preparing N-alkyl-nitroanilines | UNION CARBIDE CORPORATION (US) | 1981-09-15 | — | — | US | claimed |
| US-20250250229-A1 | ARYLTHIO DERIVATIVES WITH PHARMACOLOGICAL ACTIVITY | IRIDEA S.R.L. (IT) | 2025-08-07 | — | — | US | disclosed |
| CN-120060157-A | Hybridoma cell strain secreting tervelol monoclonal antibody and application thereof | 江南大学 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024190869-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | デンカ株式会社 | 2024-09-19 | — | — | WO | disclosed |
| CN-114480295-B | Hybridoma cell strain secreting anti-butralin monoclonal antibody and application thereof | 江南大学 | 2023-08-22 | — | — | CN | disclosed |
| US-11673130-B2 | Catalyst system containing a metathesis catalyst and at least one phenolic compound and a process for metathesis of nitrile-butadiene rubber (NBR) using the catalyst system | ARLANXEO DEUTSCHLAND GMBH (DE) | 2023-06-13 | — | — | US | disclosed |
| EP-3440073-B1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LTD (GB) | 2022-06-08 | — | — | EP | disclosed |
| CN-114480295-A | Hybridoma cell strain capable of secreting butralin-resistant monoclonal antibody and application thereof | 江南大学 | 2022-05-13 | — | — | CN | disclosed |
| US-20220032279-A1 | CATALYST SYSTEM CONTAINING A METATHESIS CATALYST AND AT LEAST ONE PHENOLIC COMPOUND AND A PROCESS FOR METATHESIS OF NITRILE-BUTADIENE RUBBER (NBR) USING THE CATALYST SYSTEM | ARLANXEO DEUTSCHLAND GMBH (DE) | 2022-02-03 | — | — | US | disclosed |
| US-5777168-A | Process for producing N-alkyl-dinitroalkylanilines | SRM CHEMICAL, LTD. CO. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5689006-A | Process for producing n-alkyl-dinitroalkylanilines | SRM CHEMICAL, LTD. CO. (US) | 1997-11-18 | — | — | US | disclosed |
| US-5663441-A | Production of mono-N-alkyl-dinitroalkylanilines and N-alkyl-dinitroaniline derivatives | SRM CHEMICAL, LTD. CO. (US) | 1997-09-02 | — | — | US | disclosed |
| WO-1997001527-A1 | PRODUCTION OF MONO-N-ALKYL-DINITROALKYLANILINES AND N-ALKYL-DINITROANILINE DERIVATIVES | SYNTECH LTD. CO. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-4395572-A | Process for preparing N-alkyl-nitroanilines | UNION CARBIDE CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
| US-4289907-A | Process for preparing N-alkyl-nitroanilines | UNION CARBIDE CORPORATION (US) | 1981-09-15 | — | — | US | disclosed |
| US-4077795-A | 2,4-DINITROANILINE DERIVATIVES | UNION CARBIDE CORPORATION (US) | 1978-03-07 | — | — | US | disclosed |
| US-3991116-A | HERBICIDES AND PISCICIDES | AMCHEM PRODUCTS, INC. (US) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250229-A1 | ARYLTHIO DERIVATIVES WITH PHARMACOLOGICAL ACTIVITY | FPR1, FPR3, FPR2 | GPR35 161/4885MEN1 4835/4885KMT2A 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.